Chardan Capital Reiterates Buy Rating for Prime Medicine (NASDAQ:PRME)

Posted by Brenda Bartman on Sep 25th, 2026

Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a report released on Friday, Benzinga reports. They currently have a $7.00 target price on the stock. Chardan Capital’s price objective would indicate a potential upside of 141.38% from the company’s current price.

Several other research firms have also weighed in on PRME. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a report on Friday. Wall Street Zen upgraded shares of Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. BMO Capital Markets started coverage on shares of Prime Medicine in a report on Tuesday, August 18th. They set an “outperform” rating and a $9.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Prime Medicine in a report on Monday, August 10th. Finally, The Goldman Sachs Group set a $6.00 target price on shares of Prime Medicine in a report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Prime Medicine currently has a consensus rating of “Moderate Buy” and an average target price of $7.47.

View Our Latest Research Report on Prime Medicine

Prime Medicine Trading Down 5.5%

Shares of PRME traded down $0.17 during mid-day trading on Friday, reaching $2.90. The company had a trading volume of 7,071,219 shares, compared to its average volume of 2,940,198. The stock has a market cap of $526.00 million, a price-to-earnings ratio of -2.74 and a beta of 2.34. The firm has a fifty day simple moving average of $3.25 and a 200-day simple moving average of $3.37. Prime Medicine has a fifty-two week low of $2.67 and a fifty-two week high of $6.94.

Prime Medicine (NASDAQ:PRME – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $4.40 million. Prime Medicine had a negative net margin of 4,613.11% and a negative return on equity of 188.27%. As a group, equities analysts predict that Prime Medicine will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Prime Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alphabet Inc. purchased a new stake in Prime Medicine during the 2nd quarter worth $61,116,000. BlackRock Inc. purchased a new stake in Prime Medicine during the 2nd quarter worth $35,432,000. ADAR1 Capital Management LLC purchased a new stake in Prime Medicine during the 2nd quarter worth $7,371,000. MWG Caph Ltd bought a new stake in shares of Prime Medicine in the 4th quarter worth about $6,219,000. Finally, Redmile Group LLC bought a new stake in shares of Prime Medicine in the 1st quarter worth about $5,536,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

About Prime Medicine

(Get Free Report)

Prime Medicine, Inc is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient.